A knowledge-based SME founded in 2009, with headquarters in Monteriggioni (SI) and Office/Laboratory at the “Toscana Life Sciences” (TLS) Science Park since 2011. Microbiotec is a Start-up company based on the technology and innovation developed at the Laboratory of Molecular Microbiology and Biotechnology of the University of Siena. The company works in the fields of microbial biotechnology, probiotics, vaccines and diagnostics.
Current research activities include projects on Microbial Biotechnology with focus on bacterial lysates, probiotics based on Lactobacilli, vaccines formulations and new diagnostics. From 2015, Microbiotec has implemented several methods for transcriptome analysis of RNA Sequencing data for study the human immune response to Ebola vaccine.
Microbiotec has been Partner in many EU Projects as CHAARM (Combined Highly Active Anti-Retroviral Microbiocides), ADITEC (Advanced Immunization Technologies) and MOTIF (Microbicide Optimization Through Innovative Formulation). Actually is engaged in VSV-EBOVAC (Vaccine safety and immunogenicity signature of human responses to VSV-ZEBOV), VSV-EBOPLUS (Systems analysis of adult and pediatric response to the VSV-ZEBOV Ebola vaccine) funded by IMI2 and VacPath (Novel vaccine vectors to resist pathogen challenge) in the Marie Skłodowska-Curie Innovative Training Networks.